Skip to main content
Fig. 8 | Molecular Cancer

Fig. 8

From: Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways

Fig. 8

Syndecan-1 regulates expression of Notch-1 &-2 in SUM-149 cells. a A representative flow cytometric analysis for the expression of Syndecan-1 and Notch-2 in SUM-149 and SKBR-3. b Quantitative analysis of four subpopulations; Notch-2(-)Syndecan-1(-), Notch-2(+)Syndecan-1(-), Notch-2(-)Syndecan-1(+) and Notch-2(+)Syndecan-1(+). Data represent mean ± SEM, n ≥ 3. * P < 0.05, ** P < 0.01 as determined by Student’s t-test. c Syndecan-1 knockdown downregulates expression level of Notch-1 protein analyzed by Western blot (left panel) and Notch-2 protein analyzed by flow cytometry (right panel) in SUM-149 cells. Black line: unstained cells, red line: control cells, blue line: Syndecan-1 knockdown cells. * P < 0.05 as determined by Student’s t-test. Data shown are a single experiment representative of three independent experiments. d IL-6, IL-8, gp130 and Hey-1 mRNA levels post GSI treatment in SUM-149 cells. Data represent mean ± SEM, n ≥ 3. * P < 0.05, ** P < 0.01 and # P < 0.001 as determined by one-way ANOVA followed by Tukey’s multiple comparison test

Back to article page